A continuation and new results from November 2 post.
SOUTH SAN FRANCISCO, Calif.-- Exelixis, Inc. announced that clinical investigators will discuss clinical data on XL999, XL880, XL820 and XL184 in conjunction with data presentations at the 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" to be held in Prague, Czech Republic at 6:00 p.m. (local time) / 12:00 p.m. (ET) / 9:00 a.m. (PT) on Thursday, November 9, 2006.
So what are these XL... drugs and what do they do?
XL999 is an inhibitor of a receptor tyrosine kinase called VEGF, (vascular endothelial growth factor) which tells cells for form new blood vessels. It also inhibits other receptors that tells cells to grow.
XL880 stops VEGFR2 (vascular endothelial growth factor receptor 2) anther receptor that is overexpressed and upregulated in tumor cells that are growing rapidly and need to feed themselves with new blood vessels.
XL820 is a inhibitor of mutationally activated forms of KIT found in human cancers. In tumor models of breast carcinoma, glioma and leukemia the compound exhibits dose-dependent growth inhibition and has been shown to cause tumor regression.
KIT is another receptor tyrosine kinase that binds and signals when stem cell growth factor binds to it. In tumors, it is mutated such that it continually sends signals to the nucleus.
XL184 inhibits VEGFR2 and Met, key drivers for tumor formation and growth. MET receptor is a tyrosine kinase that transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.
(EXEL) closed up 35 cents friday, at $8.56. I'm watching this one and may get in before the data is announced.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment